|By Marketwired .||
|May 12, 2014 06:00 AM EDT||
LONDON, ONTARIO -- (Marketwired) -- 05/12/14 -- Sernova Corp. (TSX VENTURE: SVA) is pleased to announce that Mr. Kevin M. Egan, President, Borealis Biotechnology LLC, an international biotechnology consulting company, has joined Sernova as Chair of the Business Advisory Board. A Washington-based entrepreneur and investor, Mr. Egan is one of North America's most prolific, biotech entrepreneurs, bringing over 25 years of success-driven experience in biopharma, and commercialization & partnering expertise to Sernova. He has been directly involved in helping to develop blockbuster drugs from two, bell-weather US biotech giants: Amgen and Icos.
"We are elated to have a seasoned biotech business development colleague join Sernova at this exciting juncture", remarked Dr. Philip Toleikis, President & CEO.
"In addition to Cialis, Mr. Egan worked on two Amgen blockbuster drugs - Epogen, also known as Erythropoietin, which is a red blood cell hormone used primarily for treating people with anemia caused by a variety of diseases; and Neupogen - also known as GCSF, which is a white blood cell growth factor used extensively during chemotherapy. These biopharmaceuticals, along with their derivatives, are among the biggest selling pharmaceuticals of all time", added Dr. Toleikis.
"I am pleased to be joining Sernova at a time when pharma is looking for disruptive technologies to bolster their pipelines," said Mr. Egan. "I am looking forward to working with Dr. Toleikis, and the industry-recognized team he has assembled, to advance Sernova's therapeutic cell-based product development programs and drive value for shareholders."
Mr. Egan began his career at Amgen, Inc. where he worked in research for ten years. In addition to negotiating licensing, partnering, and outsourcing agreements for both biologics and small molecules he was responsible for building and running ICOS' biologics manufacturing business including marketing, business development, and managing the P&L. Over the course of his career, Mr. Egan has negotiated and closed over 100 contracts and agreements with companies from the U.S., Canada, Europe, Australia, Israel, Japan and Taiwan. To date he has brought in over $150M in revenue for various contract manufacturing organizations.
Mr. Egan has an MBA from the University of Washington, a Master's degree in Biochemistry and Molecular Biology from U.C. Santa Barbara, and undergraduate degrees in Biology and Chemistry from U.C. Santa Cruz.
Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch, an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova's proprietary local immune protection technology.
Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
May. 24, 2016 01:45 PM EDT Reads: 1,339
May. 24, 2016 01:45 PM EDT Reads: 2,033
May. 24, 2016 01:45 PM EDT Reads: 840
May. 24, 2016 01:30 PM EDT Reads: 1,716
May. 24, 2016 01:30 PM EDT Reads: 942
May. 24, 2016 01:15 PM EDT Reads: 635
May. 24, 2016 01:00 PM EDT Reads: 820
May. 24, 2016 12:45 PM EDT Reads: 812
May. 24, 2016 12:00 PM EDT Reads: 3,231
May. 24, 2016 11:00 AM EDT Reads: 1,424
May. 24, 2016 10:30 AM EDT Reads: 672
May. 24, 2016 09:30 AM EDT Reads: 1,668
The demand for organizations to expand their infrastructure to multiple IT environments like the cloud, on-premise, mobile, bring your own device (BYOD) and the Internet of Things (IoT) continues to grow. As this hybrid infrastructure increases, the challenge to monitor the security of these systems increases in volume and complexity. In his session at 18th Cloud Expo, Stephen Coty, Chief Security Evangelist at Alert Logic, will show how properly configured and managed security architecture can...
May. 24, 2016 09:00 AM EDT Reads: 1,947
In his session at 18th Cloud Expo, Andrew Cole, Director of Solutions Engineering at Peak 10, will discuss how the newest technology advances are reducing the cost and complexity of traditional business continuity and disaster recovery solutions. Attendees will: Learn why having a full disaster recovery strategy is more important now than ever before Explore the key drivers of a successful disaster recovery solution Achieve measurable operational and business value from a disaster recovery ...
May. 24, 2016 09:00 AM EDT Reads: 1,204
SYS-CON Events announced today the Docker Meets Kubernetes – Intro into the Kubernetes World, being held June 9, 2016, in conjunction with 18th Cloud Expo | @ThingsExpo, at the Javits Center in New York, NY. Register for 'Docker Meets Kubernetes Workshop' Here! This workshop led by Sebastian Scheele, co-founder of Loodse, introduces participants to Kubernetes (container orchestration). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, participants learn ...
May. 24, 2016 09:00 AM EDT Reads: 1,780